Cost analysis of ventilator-associated pneumonia in Turkish medical-surgical intensive care units
Author：Hicran Karaoglan et al
Le Infezioni in Medicina 2010, (4)：248-255
報告者：王容芝
指導者：鄭瑞駿 組長
報告日期：101年02月15日
A study was carried
out to assess treatment success and the overall costs of patients with
ventilator-associated pneumonia (VAP). In a prospective case control study,
data were collected from 25 intensive care unit (ICU) beds. A total of 162 ICU
patients who required mechanical ventilation were assessed. Of these, 81
patients were diagnosed with VAP and the other 81 were controls (without VAP).
Risk of mortality was analyzed and total cost of care was recorded. Age, sex
and underlying disease were similar between the groups. The mean length of stay
(LOS) in the ICUs in the VAP cases (15.7±9.1 days) exceeded that of the
controls (4.9±4.9 days) (p<0.0001), and the additional LOS attributable to
VAP was estimated at 10.8 days. In the VAP group, 25 patients had early-onset
VAP, and the other 56 patients had late-onset VAP. Mortality rates were higher
in VAP patients (32%) than controls (19.7%) p<0.05). Total costs were USD
8602.7±5045.5 in the VAP group and USD 2621.9±2053.3 in controls. The
additional cost for VAP was found to be USD 5980 per patient. These data
suggest that morbidity, mortality, ICU length of stay and costs increase with
VAP. The additional costs for VAP are especially based on the use of novel and
expensive antibiotics, other drugs, and medical material.
A study was carried
out to assess treatment success and the overall costs of patients with
ventilator-associated pneumonia (VAP). In a prospective case control study,
data were collected from 25 intensive care unit (ICU) beds. A total of 162 ICU
patients who required mechanical ventilation were assessed. Of these, 81
patients were diagnosed with VAP and the other 81 were controls (without VAP).
Risk of mortality was analyzed and total cost of care was recorded. Age, sex
and underlying disease were similar between the groups. The mean length of stay
(LOS) in the ICUs in the VAP cases (15.7±9.1 days) exceeded that of the
controls (4.9±4.9 days) (p<0.0001), and the additional LOS attributable to
VAP was estimated at 10.8 days. In the VAP group, 25 patients had early-onset
VAP, and the other 56 patients had late-onset VAP. Mortality rates were higher
in VAP patients (32%) than controls (19.7%) p<0.05). Total costs were USD
8602.7±5045.5 in the VAP group and USD 2621.9±2053.3 in controls. The
additional cost for VAP was found to be USD 5980 per patient. These data
suggest that morbidity, mortality, ICU length of stay and costs increase with
VAP. The additional costs for VAP are especially based on the use of novel and
expensive antibiotics, other drugs, and medical material.
沒有留言:
張貼留言